GGHC
AMED

Gilder Gagnon Howe & Co’s Amedisys AMED Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-819,433
Closed -$51.5M – 285
2017
Q2 		$51.5M Sell
819,433
-12,274
-1% -$715K 0.76% 44
2017
Q1 		$42.5M Buy
831,707
+7,505
+0.9% +$358K 0.72% 44
2016
Q4 		$35.1M Sell
824,202
-72,235
-8% -$3.07M 0.69% 47
2016
Q3 		$42.5M Buy
+896,437
New +$44.7M 0.73% 46

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gilder Gagnon Howe & Co's AMED Position: Q3 2017 in Review

Gilder Gagnon Howe & Co sold out of Amedisys (AMED) in Q3 2017, closing a stake of 819,433 shares — an estimated $51.5M sold.

Gilder Gagnon Howe & Co first reported a position in AMED in Q3 2016 and held it in 4 quarters. The position peaked at $51.5M in Q2 2017. 163 funds tracked by Wall St. Rank hold AMED as of Q3 2017.

  • Gilder Gagnon Howe & Co reported no remaining Amedisys position as of Q3 2017 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 819,433 Amedisys shares in Q3 2017, an estimated $51.5M.
  • Gilder Gagnon Howe & Co first reported a position in Amedisys in Q3 2016 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's Amedisys position peaked at $51.5M in Q2 2017.
  • 163 funds tracked by Wall St. Rank held Amedisys as of Q3 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2017, filed 6 Nov 2017.